Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
about
Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysisNew approaches in the management of chronic hepatitis B: role of tenofovir.Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals.The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.Experience with tenofovir disoproxil fumarate for antiretroviral therapy.Tenofovir for the treatment of hepatitis B virus.Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapyVirology and clinical sequelae of drug-resistant HBV in HIV-HBV-coinfected patients on highly active antiretroviral therapy.HIV/HBV co-infection and rate of antiretroviral treatment change after highly active antiretroviral treatment initiation in a cohort of HIV-infected patients in Greece.Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents.More improvement than progression of liver fibrosis following antiretroviral therapy in a longitudinal cohort of HIV-infected patients with or without HBV and HCV co-infections.Tenofovir and its potential in the treatment of hepatitis B virus.Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer?Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with responseHepatitis B Virus Seroprevalence and Serology Patterns in a Cohort of HIV Positive Individuals from Harare, Zimbabwe
P2860
Q34409132-512B6D16-7236-4FF9-AFD3-B47EADADDEB6Q34847029-5EEBAEF5-42DB-4821-9392-9AB4E4638BC6Q35026531-1E64A13F-3B90-40F9-B08A-D8754D7E3837Q35433965-17480315-A55A-425F-99E8-8E23BFB5F36CQ36691295-8C954D11-E721-4B04-99D5-5C609917528EQ37142078-B4FE0846-4546-442C-B98A-76387798EB92Q37605886-0B9F0A24-65B8-427D-82B6-51E9327F8523Q37632321-0A61C840-184E-46A3-B95B-0114782E030BQ37762108-32E6A57E-0AE5-4BBF-9E58-063794DD0310Q38441522-75E5B574-8922-44CF-8312-4EDE71D68322Q40398857-1E4B48BA-864D-40A1-AD28-52E831102D42Q40420627-8D191F7A-D8FF-4F5E-A756-E0888F8916C5Q41435482-4A836004-BB14-46BE-BA6A-7C660668D3ADQ42843222-73C921E4-8D60-4B80-BFAB-80E85B835260Q58646483-AAF89ED5-1D86-4748-8F20-4CD95B86A93EQ59050935-EAC77BC0-2533-44F1-BC85-C0C63AF526F3
P2860
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Impact of tenofovir-containing ...... human immunodeficiency virus.
@en
Impact of tenofovir-containing ...... human immunodeficiency virus.
@nl
type
label
Impact of tenofovir-containing ...... human immunodeficiency virus.
@en
Impact of tenofovir-containing ...... human immunodeficiency virus.
@nl
prefLabel
Impact of tenofovir-containing ...... human immunodeficiency virus.
@en
Impact of tenofovir-containing ...... human immunodeficiency virus.
@nl
P2093
P356
P1476
Impact of tenofovir-containing ...... human immunodeficiency virus.
@en
P2093
Amina Carlebach
Annemarie Berger
Christoph Stephan
Markus Bickel
Martin Stuermer
Schlomo Staszewski
Stephan Klauke
Thomas Lutz
P304
P356
10.1093/JAC/DKI396
P407
P577
2005-11-03T00:00:00Z